A subgroup analysis of a phase 3 trial suggests that eribulin significantly improves survival outcomes compared with dacarbazine in patients with pretreated liposarcoma—a soft-tissue sarcoma subtype with very few efficacious therapies.

中文翻译：

---

依立布林：脂肪肉瘤的有效治疗选择

一项3期临床试验的亚组分析表明，与达卡巴嗪相比，在预先治疗的脂肪肉瘤（一种软组织肉瘤亚型，几乎没有有效的疗法）的患者中，eribulin显着改善了生存结果。